MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Exelixis Total Liabilities 2011-2026 | EXEL
Annual Total Liabilities Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 683 M | 703 M | 678 M | 583 M | 406 M | 200 M | 200 M | 135 M | 370 M | 437 M | 437 M | 443 M | 437 M | 425 M | 303 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 703 M | 135 M | 429 M |
Quarterly Total Liabilities Exelixis
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 658 M | 683 M | 663 M | 645 M | 706 M | 703 M | 685 M | 653 M | 676 M | 678 M | 629 M | 615 M | 588 M | 583 M | 470 M | 490 M | 360 M | 406 M | 335 M | 324 M | 279 M | 200 M | 259 M | 213 M | 208 M | - | 181 M | 154 M | 157 M | 135 M | 135 M | 135 M | 135 M | 370 M | 370 M | 370 M | 370 M | 506 M | 516 M | 506 M | 506 M | 473 M | 473 M | 437 M | 437 M | 483 M | 443 M | 443 M | 443 M | 483 M | 437 M | 437 M | 437 M | 476 M | 425 M | 425 M | 425 M | 303 M | 303 M | 303 M | 303 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 706 M | 135 M | 427 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
6.06 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
6.56 M | - | 1.35 % | $ 17.8 M |  China |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.22 | 1.37 % | $ 207 M |  Israel |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
197 M | $ 1.58 | 7.14 % | $ 185 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
2.76 B | $ 89.59 | 1.29 % | $ 21.7 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
71.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
330 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
104 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
35.1 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | - | - | $ 1.99 B | USA |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
38 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.34 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
34.2 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
281 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
42.3 M | $ 14.79 | 2.64 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
2.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | - | - | $ 5.2 M | Israel |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 56.95 | 9.35 % | $ 5.12 B |  Schweiz |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 21.95 | 2.81 % | $ 2.79 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |